Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery
Inflammatory bowel disease (IBD) is a complex disease that is associated with multiple genetic and environmental variables. Here the authors develop genetically engineered probiotics with selfproducing functional proteins and biofilm self-coating for safe and efficient IBD treatment in mice.
Main Authors: | Jun Zhou, Maoyi Li, Qiufang Chen, Xinjie Li, Linfu Chen, Ziliang Dong, Wenjun Zhu, Yang Yang, Zhuang Liu, Qian Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-06-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-31171-0 |
Similar Items
-
Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease
by: Lingfeng Li, et al.
Published: (2022-09-01) -
Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease
by: Yongjia Hu, et al.
Published: (2022-12-01) -
Inflammatory Bowel Diseases and Gut Microbiota
by: Yuri Haneishi, et al.
Published: (2023-02-01) -
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease
by: Xue Guo, et al.
Published: (2022-01-01) -
Exploring the Benefits of Probiotics in Gut Inflammation and Diarrhea—From an Antioxidant Perspective
by: Qihui Li, et al.
Published: (2023-06-01)